Athira Pharma, Inc. — Director's Dealing 2022

Dec 7, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-12-02

Reporting Person: Romano Kelly A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-02	Common Stock	P	30000	$3.29	Acquired	38315	Direct

Footnotes

F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.23 to $3.31, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.